vimarsana.com

Page 61 - கதிர்வீச்சு புற்றுநோயியல் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Henry Ford Cancer Institute Set to Begin Patient Care at Brigitte Harris Cancer Pavilion

Henry Ford Cancer Institute Set to Begin Patient Care at Brigitte Harris Cancer Pavilion The new 187,000-square-foot facility offers the most advanced cancer treatment options available, convenient access to clinical trials News provided by Share this article Share this article DETROIT, Jan. 19, 2021 /PRNewswire/  The Henry Ford Cancer Institute at Henry Ford Health System will open the doors of the new Brigitte Harris Cancer Pavilion on Jan. 20, 2021. Connected to Henry Ford Hospital by the Nancy Vlasic Skywalk over West Grand Boulevard, the new cancer pavilion is a global destination for seamless and integrated cancer care, bringing together the newest and most innovative treatment options including specialty clinics for 14 different types of cancer, precision medicine, clinical trials and supportive services.

Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer

Share this article Share this article SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/  Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the TomoTherapy ® System. The study, published online in the International Journal of Radiation Oncology Biology Physics, also reported that the once-daily schedule was associated with a very low incidence of acute and late toxicities. The TomoTherapy platform, including the next-generation Radixact ® System, is the first in the world capable of helical radiation delivery. Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivering from a full 360 degrees around the patient as the treatment table also moves at a deliberate pace, providing greater control of the radiation dose so it

Dartmouth Researchers Pilot FLASH Radiotherapy Beam Development for Treatment of Cancer

A joint team of researchers from Radiation Oncology at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center (NCCC), Dartmouth Engineering, and Dartmouth-Hitchcock’s Department of Surgery have developed a method to convert a standard linear accelerator (LINAC), used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam. The work, entitled “Electron FLASH Delivery at Treatment Room Isocenter for Efficient Reversible Conversion of a Clinical LINAC,” is newly published online in International Journal of Radiation Oncology, Biology & Physics. The exceptionally high dose rate is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, “FLASH.” “These high dose rates have been shown to pro

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging Getty Images January 18, 2021   Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The firs

Global Oncology Information Systems Industry

Information Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 3: World 15-Year Perspective for Oncology Information Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.